Adicet 10-Q Adds Going-Concern Warning Despite $100.9M Cash Into 2H 2027
ACET is trading near its 52-week low of $2.87 (2.8% above the low) on elevated volume (2.0× avg).
Summary
Adicet's Q3 10-Q confirms the $18.9M loss and $100.9M cash reported in the same-day 8-K, but adds a formal substantial-doubt going-concern conclusion — another financing will be needed to get past the second half of 2027.
Key Events · Earnings and Guidance · ACET
-
Going-Concern Doubt Disclosed
The 10-Q states the Company concluded substantial doubt exists about its ability to continue as a going concern, as current cash and short-term investments may not fund operations for at least twelve months from issuance.
-
Q3 Loss Narrows to $18.9M
Net loss was $18.9M ($1.76 per share) versus $26.9M ($4.72) a year earlier, with R&D down to $15.6M from $22.9M and G&A to $4.2M from $5.1M.
-
Cash Runway Into Second Half 2027
Cash, cash equivalents and short-term treasury investments totaled $100.9M at September 30, 2026, down from $158.5M at December 31, 2025; management says this funds operations into 2H 2027.
-
Vendor Dispute Disclosed
The Company is in an ordinary-course proceeding with a former vendor over service-related charges; it cannot reasonably estimate the possible loss or range of loss.
Analysis · ACET · Life Sciences
The Q3 numbers were already out via the same-day 8-K: net loss narrowed to $18.9M from $26.9M, and cash plus short-term investments stood at $100.9M, which management says funds operations into the second half of 2027. What is new in the 10-Q is the formal going-concern conclusion — the company states its current cash and investments may not be sufficient to fund operations for at least twelve months from issuance — meaning another raise is required and dilution risk is live. The filing also discloses an ordinary-course vendor dispute with no estimable loss. With the stock near its 52-week low, the going-concern language is the fact that matters: the lupus pivotal study and the 4Q 2026 FDA meeting are funded, but only through the runway, not to approval.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ACET was trading at $2.95 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $27.3M. The 52-week trading range was $2.87 to $11.37. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.